December 19, 2015 /
Akaal
Pharma, a developer of small molecule drugs for the treatment of inflammation
and autoimmune diseases including multiple sclerosis (MS), recently announced
highly positive preclinical trial results on the safety and efficacy of its
drug candidate AKP-11 when compared to Gilenya (fingolimod, FTY-720), an oral
MS drug approved by the U.S. Food and Drug Administration […]
Pharma, a developer of small molecule drugs for the treatment of inflammation
and autoimmune diseases including multiple sclerosis (MS), recently announced
highly positive preclinical trial results on the safety and efficacy of its
drug candidate AKP-11 when compared to Gilenya (fingolimod, FTY-720), an oral
MS drug approved by the U.S. Food and Drug Administration […]
The post New MS Drug Shows ‘Excellent Profile’ in Preclinical Tests
Against Approved Therapy appeared first on Multiple Sclerosis News Today.
Against Approved Therapy appeared first on Multiple Sclerosis News Today.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Keep up to date with the news and information we provide
by signing up by clicking here
.===================================
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT
